[
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock rises Friday, still underperforms market",
    "summary": "Eli Lilly & Co. stock rises Friday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=60af084ee41a8446314cea80f0fcf5c664bddb918921bc66899cbb7c71b178e7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735921980,
      "headline": "Eli Lilly & Co. stock rises Friday, still underperforms market",
      "id": 132321545,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock rises Friday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=60af084ee41a8446314cea80f0fcf5c664bddb918921bc66899cbb7c71b178e7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=d97093db5a279d85d4704528595e030be266375e2e58707cefc4538c9a077b4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735912821,
      "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
      "id": 132257188,
      "image": "https://media.zenfs.com/en/zacks.com/a41b81fe729c761f3f94f42ff348f70c",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=d97093db5a279d85d4704528595e030be266375e2e58707cefc4538c9a077b4e"
    }
  },
  {
    "ts": null,
    "headline": "From Davids to Goliaths: the GLP-1R gold rush",
    "summary": "There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.",
    "url": "https://finnhub.io/api/news?id=f0597190b847720f110eaa96df6726d5a1290b22bc3d12947dfe474ff30ab385",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735910418,
      "headline": "From Davids to Goliaths: the GLP-1R gold rush",
      "id": 132253552,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2025/01/shutterstock_2520433547.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.",
      "url": "https://finnhub.io/api/news?id=f0597190b847720f110eaa96df6726d5a1290b22bc3d12947dfe474ff30ab385"
    }
  },
  {
    "ts": null,
    "headline": "Amphastar Pharmaceuticals: Cheap With Caveats",
    "summary": "Amphastar Pharmaceuticals' stock has declined over 25% since early November, despite solid earnings and sales growth. Click here to find out why AMPH is a Hold.",
    "url": "https://finnhub.io/api/news?id=3d86ce0fb7e8ef8e751735952af173a8e96efbd368af54b2a60f25a0f6e21d3c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735908513,
      "headline": "Amphastar Pharmaceuticals: Cheap With Caveats",
      "id": 132255501,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1281832252/image_1281832252.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Amphastar Pharmaceuticals' stock has declined over 25% since early November, despite solid earnings and sales growth. Click here to find out why AMPH is a Hold.",
      "url": "https://finnhub.io/api/news?id=3d86ce0fb7e8ef8e751735952af173a8e96efbd368af54b2a60f25a0f6e21d3c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'",
    "summary": "As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has now ordered the Outsourcing Facilities Association to respond by January 15, with Eli Lilly’s reply due by January 21. What happened: In early October, the FDA determined that Eli Lilly’s tirzepatide injection shortage had been resolved. The U.S. health regulator reminded compounders of",
    "url": "https://finnhub.io/api/news?id=adaf8a9be9e6a0766d277dcafaac93719395e3d869b3aa5502c97bfdba500a90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735908383,
      "headline": "Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'",
      "id": 132257191,
      "image": "https://media.zenfs.com/en/Benzinga/74d837b99855956bf225592e5dea9ec1",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has now ordered the Outsourcing Facilities Association to respond by January 15, with Eli Lilly’s reply due by January 21. What happened: In early October, the FDA determined that Eli Lilly’s tirzepatide injection shortage had been resolved. The U.S. health regulator reminded compounders of",
      "url": "https://finnhub.io/api/news?id=adaf8a9be9e6a0766d277dcafaac93719395e3d869b3aa5502c97bfdba500a90"
    }
  },
  {
    "ts": null,
    "headline": "Silence Therapeutics: Simply No Match For Its Orally Dosed Rival (Downgrade)",
    "summary": "Silence Therapeutics plc's Zerlasiran has done well, but Eli Lilly's Muvalaplin is simply better. Read more about SLN stock update.",
    "url": "https://finnhub.io/api/news?id=540da37b5e8aac853d1413525535a618670b6992a6068e3a423020157de6a39d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735906716,
      "headline": "Silence Therapeutics: Simply No Match For Its Orally Dosed Rival (Downgrade)",
      "id": 132255118,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1475830028/image_1475830028.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Silence Therapeutics plc's Zerlasiran has done well, but Eli Lilly's Muvalaplin is simply better. Read more about SLN stock update.",
      "url": "https://finnhub.io/api/news?id=540da37b5e8aac853d1413525535a618670b6992a6068e3a423020157de6a39d"
    }
  },
  {
    "ts": null,
    "headline": "VONG: Time To Take Some Gains",
    "summary": "Vanguard Russell 1000 Growth Index Fund ETF holds 394 large- and mid-cap stocks, heavily concentrated in technology and top holdings. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=2249f04ec45e2f92df470f647b2178e69ab116f51077dfa0091a85f45c23d81b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735891200,
      "headline": "VONG: Time To Take Some Gains",
      "id": 132252645,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155437849/image_155437849.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Vanguard Russell 1000 Growth Index Fund ETF holds 394 large- and mid-cap stocks, heavily concentrated in technology and top holdings. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=2249f04ec45e2f92df470f647b2178e69ab116f51077dfa0091a85f45c23d81b"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer",
    "summary": "Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=19a8f5d3363fd6f907ef59b816f30cbc03162df4407ca23c13c9dd0cb1d9b032",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735890300,
      "headline": "The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer",
      "id": 132249155,
      "image": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=19a8f5d3363fd6f907ef59b816f30cbc03162df4407ca23c13c9dd0cb1d9b032"
    }
  }
]